Immunogenic Cell Death: the Key to Unlocking the Potential for Combined Radiation and Immunotherapy

Area of Science:

• Immunology
• Cancer Research
• Mathematical Modeling

Background:

• Immunogenic cell death (ICD) releases tumor antigens and activates anti-tumor immunity, but its role in combination therapies is understudied.
• Radiotherapy (RT) and macrophage-based immunotherapy are key cancer treatments, with potential synergy through ICD.

Purpose of the Study:

• To develop a mathematical model quantifying ICD's role in optimizing combined RT and macrophage immunotherapy.
• To investigate the efficacy of targeting the SIRPα-CD47 checkpoint in preclinical models.

Main Methods:

• Development of a mathematical model to assess ICD in combination therapy.
• Utilizing preclinical murine data with a focus on the SIRPα-CD47 checkpoint.
• Evaluating radiotherapy (RT) alone versus combined approaches.

Main Results:

• RT alone induced minimal ICD; disrupting the SIRPα-CD47 axis significantly enhanced phagocytosis and immune activation.
• The model predicted an optimal RT dose (6-8 Gy) for maximizing ICD and a dose-dependent abscopal effect.
• SIRPα-knockout macrophages demonstrated superior tumoricidal activity compared to other treatment combinations.

Conclusions:

• A quantitative framework was established for designing effective combination therapies.
• Leveraging ICD enhances immune checkpoint inhibition and radiotherapy synergy for improved cancer treatment.
• Targeting the SIRPα-CD47 axis with macrophages and optimized RT shows significant anti-tumor potential.